4D Molecular Therapeutics Inc (FDMT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -68,760 | -140,109 | -159,506 | -102,630 | -47,972 |
| Depreciation Amortization | 135 | -40 | -109 | -216 | -216 |
| Accounts payable and accrued liabilities | 3,533 | 6,773 | 2,477 | 4,314 | -235 |
| Other Working Capital | -4,751 | 6,172 | 3,417 | -1,582 | -7,171 |
| Other Operating Activity | 1,718 | 18,122 | 16,088 | 8,979 | 7,836 |
| Operating Cash Flow | $-68,125 | $-109,082 | $-137,633 | $-91,135 | $-47,758 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | 11 | -536 | -606 | -697 | -631 |
| Purchase Of Investment | -33,519 | -442,821 | -264,721 | -249,480 | -134,077 |
| Sale Of Investment | 102,396 | 350,384 | 301,201 | 268,273 | 166,656 |
| Investing Cash Flow | $68,888 | $-92,973 | $35,874 | $18,096 | $31,948 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 11,484 | 19,420 | 978 | 862 | N/A |
| Other Financing Activity | 0 | 93,540 | 0 | 0 | 0 |
| Financing Cash Flow | $11,484 | $112,960 | $978 | $862 | $N/A |
| Beginning Cash Position | 60,241 | 149,336 | 149,336 | 149,336 | 149,336 |
| End Cash Position | 72,488 | 60,241 | 48,555 | 77,159 | 133,526 |
| Net Cash Flow | $12,247 | $-89,095 | $-100,781 | $-72,177 | $-15,810 |
| Free Cash Flow | |||||
| Operating Cash Flow | -68,125 | -109,082 | -137,633 | -91,135 | -47,758 |
| Capital Expenditure | 11 | -536 | -606 | -697 | -631 |
| Free Cash Flow | -68,114 | -109,618 | -138,239 | -91,832 | -48,389 |